skip navigation links
National Cancer Institute
EVS Logo NCI Term Browser Enterprise Vocabulary Services
Terminologies Value Sets Mappings
Version: 17.12d (Release date: 2017-12-26)
SearchBox Top
SearchBox Bottom
Lactobacillus brevis CD2 Lozenge (Code C99229)

Terms & Properties Synonym Details Relationships Mapping View All  
Terms & Properties

Preferred Name: Lactobacillus brevis CD2 Lozenge

Definition: A lozenge containing an extract from the Lactobacillus brevis (L. brevis) with potential anti-inflammatory activity. As L. brevis CD2 contains high levels of arginine deiminase, which catalyzes the conversion of arginine to citrulline and ammonia, administration of this lozenge leads to hydrolysis of arginine in the oral cavity. The growth of bacteria, which depends on arginine, is halted, polyamine biosynthesis is reduced and the production of nitric oxide (NO) is reduced. The reduction in NO generation may further prevent inflammation in the oral cavity. Therefore, this agent may be able to reduce chemo- and radiotherapy-induced mucositis.

Display Name: Lactobacillus brevis CD2 Lozenge

Label: Lactobacillus brevis CD2 Lozenge

NCI Thesaurus Code: C99229 (Search for linked caDSR metadata)  (search value sets)

NCI Metathesaurus Link: CL433058  (see NCI Metathesaurus info)

Synonyms & Abbreviations: (see Synonym Details)
Lactobacillus brevis CD2 Lozenge

External Source Codes: 
PDQ Closed Trial Search ID 719138
PDQ Open Trial Search ID 719138 (check for NCI PDQ open clinical trial info)

Other Properties:
     Name Value (qualifiers indented underneath)
code C99229
Contributing_Source CTRP
Semantic_Type Pharmacologic Substance

Additional Concept Data: 
Defined Fully by Roles: No  


Mainbox Bottom